抗アレルギー剤4, 5-Diphenylimidazol (DIT)の生物学的臨床的研究

概要

論文の詳細を見る
In view the large number of antihistamine preparations already presented. introduction of an antihistamine agent can only be justified when it shown that the new comer has a definite therapeutic advance. Allercur, one of the imidazold derivatives, is recommended to be superior in comparison with many other antihistamine preparations. One of my colleague Kawakami synthesized a new type of imidazole derivatives, 4, 5-Diphenylimidazole (DIT). In biological experiments DIT revealed a potent antihistamine, antiacetylcholine and a slight vasodilating activity. Toxicologic studies in mice indicate this compound is considered as quite safe for clinical application. As a clinical experiment, DIT was applied to the eczemetous patients locally in 0.2% concenration in a hydrophil vaselin base. Therapeutic results were excellent in 10 patients suffering from acute eczematous dermatitis, moderate in 17 patients, with chronic eczema. No effect was noticed in 8 cases. Topical therapy with antihistamine becomes often irritain, but as far as DIT there is no such fear. DIT was administered to 25 patients with urticaria in dosages of 5-10 mg three times daily after meals. Good to excellent results were achieved in 15, but in 10 cases the response was poor, particularly in chronic patients. Side effects were very few. Gastrointestinal upset was encountered in only one. DIT is a safe, effective antihistaminic agent with a very low incidence of such side effects as drowsiness, dryness of the mouth, which have been described with previous antihistaminic agents.
日本アレルギー学会の論文
1961-04-30

抗アレルギー剤4, 5-Diphenylimidazol (DIT)の生物学的臨床的研究

スポンサーリンク

概要

著者

関連論文

スポンサーリンク